Protalix BioTherapeutics(PLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PLX Protalix BioTherapeutics

Post-Mkt 09-04 18:27:36 EDT

2.67

+0.05

+1.91%

盘后2.65

-0.02-0.75%

17:22 EDT

High2.68	Low2.62	Vol863.20K
Open2.62	D1 Closing2.62	Amplitude2.48%
Mkt Cap214.72M	Tradable Cap204.35M	Total Shares80.42M
T/O2.29M	T/O Rate1.13%	Tradable Shares76.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PLX","market":"US","secType":"STK","nameCN":"Protalix BioTherapeutics","latestPrice":2.67,"timestamp":1788552000000,"preClose":2.62,"halted":0,"volume":863196,"hourTrading":{"tag":"盘后","latestPrice":2.65,"preClose":2.67,"latestTime":"17:22 EDT","volume":13245,"amount":35270.160831,"timestamp":1788556951465,"change":-0.02,"changeRate":-0.007491,"amplitude":0.013483},"delay":0,"changeRate":0.019083969465648786,"floatShares":76536413,"shares":80421181,"eps":0.236437,"marketStatus":"Post-Mkt","change":0.05,"latestTime":"09-04 18:27:36 EDT","open":2.62,"high":2.68,"low":2.615,"amount":2288788.8814056,"amplitude":0.024809,"askPrice":2.89,"askSize":100,"bidPrice":2.36,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.236437,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788566400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":829022400000,"exchange":"AMEX","adjPreClose":2.62,"preHourTrading":{"tag":"盘前","latestPrice":2.66,"preClose":2.62,"latestTime":"09:05 EDT","volume":868,"amount":2308.9467492,"timestamp":1788527134632,"change":0.04,"changeRate":0.015267,"amplitude":0.000038},"postHourTrading":{"tag":"盘后","latestPrice":2.65,"preClose":2.67,"latestTime":"17:22 EDT","volume":13245,"amount":35270.160831,"timestamp":1788556951465,"change":-0.02,"changeRate":-0.007491,"amplitude":0.013483},"volumeRatio":1.334682,"impliedVol":0.6587,"impliedVolPercentile":0.627},"requestUrl":"/m/hq/s/PLX/tweets","defaultTab":"tweets","newsList":[{"id":"2662277759","title":"3 Promising Penny Stocks With Over $50M Market Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2662277759","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662277759?lang=en_us&edition=fundamental","pubTime":"2026-08-26 01:05","pubTimestamp":1787677525,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the U.S. market has dropped 1.5%, but it has risen by 18% over the past year, with earnings forecasted to grow by 17% annually. For investors willing to explore beyond established names, penny stocks—often smaller or newer companies—can present intriguing opportunities despite their somewhat outdated label. By focusing on those with strong financials and a clear growth path, investors can discover promising options that balance potential upside with stability.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/3-promising-penny-stocks-with-over-50m-market-cap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/3-promising-penny-stocks-with-over-50m-market-cap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SRTS","MNOV","BK4139","PLX","PLX.AU","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159826","title":"Pelthos Therapeutics Q2 Revenue Rises on Zelsuvmi Adoption","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159826","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159826?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:20","pubTimestamp":1786620006,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Q2 revenue rises on Zelsuvmi adoptionOverviewU.S. biopharmaceutical firm's Q2 net product revenue grew 45% quarter-over-quarterNet loss for Q2 narrowed compared to Q1, adjusted EB","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OMER","PTHS","PLX","BK4007","LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156294","title":"Israel's MediWound Beats Q2 Revenue Estimates, Reaffirms 2026 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156294","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156294?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:14","pubTimestamp":1786619650,"startTime":"0","endTime":"0","summary":"Israel's MediWound beatsQ2 revenue estimates, reaffirms 2026 guidanceOverviewIsrael biotech's Q2 revenue fell but beat analyst expectationsGross profit margin declined due to one-time facility scale-u","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","ICCM","MDWD","BK4139","BK4082","VCEL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659184235","title":"Protalix (PLX) Stock Profit Swing Sharpens Focus On Elfabrio Reliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2659184235","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659184235?lang=en_us&edition=fundamental","pubTime":"2026-08-13 08:41","pubTimestamp":1786581664,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics shares jumped 7.8% to US$2.62 into the close, and that move captures only part of the story. The stock came into this print already on a strong run over the past three months. Today’s reaction, however, appears to lean more on emotion than on new information.\nThe focus is on margin and profitability. Q2 net income reached US$3.8m with earnings per share of US$0.05, supported by US$19.9m in revenue and a cash balance of about US$40.7m with no debt. The market appears...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/protalix-plx-stock-profit-swing-sharpens-focus-on-elfabrio-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/protalix-plx-stock-profit-swing-sharpens-focus-on-elfabrio-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","PLX","PLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658321974","title":"Protalix Publishes Corporate Presentation Highlighting Elfabrio Commercialization and PRX-115 Phase 2 Gout Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2658321974","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658321974?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:28","pubTimestamp":1786534092,"startTime":"0","endTime":"0","summary":"Protalix publishes corporate presentation highlighting Elfabrio commercialization and PRX-115 Phase 2 gout studyProtalix highlighted profitability with net income of $22.1 million for the first half o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLbTCF1h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971991","title":"Protalix BioTherapeutics Q2 Pretax Profit USD 4.86 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971991","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971991?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:05","pubTimestamp":1786532748,"startTime":"0","endTime":"0","summary":"Aug 12 (Reuters) - Protalix BioTherapeutics Q2 operating income USD 4.672 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 12-AUG-202610:51:00.657 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nRSD1Yp0Tq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658497152","title":"Israel's Protalix Q2 Revenue Rises on Elfabrio Sales, Reiterates 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2658497152","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658497152?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:02","pubTimestamp":1786532521,"startTime":"0","endTime":"0","summary":"Israel's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlookOverviewIsrael biopharma firm's Q2 revenue from selling goods rose yr/yr, driven by Elfabrio salesQ2 net income increased t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490CU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658979401","title":"Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658979401","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658979401?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:51","pubTimestamp":1786531899,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.12 by 58.33 percent.  The company reported quarterly sales of $19.896 million which","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61136298/protalix-biotherapeutics-q2-eps-0-05-misses-0-12-estimate-sales-19-896m-beat-12-931m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658979474","title":"Protalix Swings to Q2 Profit of USD 3.8 Million; Revenue from Selling Goods Rises 28.5% to USD 19.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658979474","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658979474?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:51","pubTimestamp":1786531869,"startTime":"0","endTime":"0","summary":"Protalix swings to Q2 profit of USD 3.8 million; revenue from selling goods rises 28.5% to USD 19.8 millionProtalix posts Q2 net income of USD 3.8 million, or USD 0.05 per share, versus USD 164,000 a ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL9gWx4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658794429","title":"Press Release: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658794429","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658794429?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:50","pubTimestamp":1786531800,"startTime":"0","endTime":"0","summary":"Company to host conference call and webcast today at 8:00 a.m. EDT-- Revenues from selling goods increased to $19.8 million in the second. quarter of 2026, up $4.4 million from the second quarter of 2025, driven. -- Total revenue climbed to $53.6 million, year to date, from $25.8 million. for the same period in 2025, which includes the previously reported $25.0. -- Year-to-date, the Company achieved profitability with a net income of. -- PRX-115 Phase 2 study continues to advance as planned, with top-line. the local marketing authorization holder.PRX-115 for Uncontrolled Gout -- RELEASE Phase 2 continues enrollmen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","BK4581","LU0868494617.USD","SG9999002224.SGD","LU0306806265.USD","LU0306807586.USD","SG9999001176.SGD","SG9999013999.USD","IE0002270589.USD","LU0456855351.SGD","LU1057294990.SGD","PFE","SG9999011175.SGD","BK4232","BK4139","LU0058720904.USD","IE00BBT3K403.USD","BK4007","LU1066051498.USD","BK4585","LU1894683264.USD","IE000M9KFDE8.USD","LU0985481810.HKD","SG9999001176.USD","BK4550","LU1883839398.USD","BK4533","BK4599","IE00BLSP4452.SGD","BK4592","LU0234572021.USD","LU0289739699.SGD","LU0321505439.SGD","LU0321505868.SGD","LU1023059063.AUD","BK4022","LU1066053197.SGD","R","BK4568","PLX","IE00B19Z3581.USD","LU2596442595.SGD","LU0170899867.USD","LU1894683348.USD","IE00B19Z3B42.SGD","LU0122379950.USD","SG9999003800.SGD","OZEM","IE00B3T34201.USD","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657545318","title":"Protalix BioTherapeutics to Report Q2 Results, Host Conference Call and Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2657545318","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657545318?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:50","pubTimestamp":1785927018,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics to report Q2 results, host conference call and webcastProtalix BioTherapeutics will release second-quarter 2026 results on Aug. 12, 2026.Management will host an earnings confe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL1p5Bkx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646386381","title":"Protalix Biotherapeutics Shareholders Approved Amended 2006 Stock Incentive Plan Share Increase to 20,975,171 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2646386381","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646386381?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:31","pubTimestamp":1782419463,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics shareholders approved amended 2006 stock incentive plan share increase to 20,975,171 sharesProtalix BioTherapeutics held its annual shareholder meeting on June 25, 2026.Shareh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDLwRBzm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644055588","title":"Barclays Keeps Their Hold Rating on PLUXEE N.V. (PLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644055588","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644055588?lang=en_us&edition=fundamental","pubTime":"2026-06-19 14:28","pubTimestamp":1781850522,"startTime":"0","endTime":"0","summary":"Barclays analyst Pravin Gondhale maintained a Hold rating on PLUXEE N.V. yesterday. The company’s shares closed yesterday at €11.98. Gondhale cover...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-pluxee-n-v-plx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-pluxee-n-v-plx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635894187","title":"Protalix BioTherapeutics posts corporate presentation outlining rare-disease portfolio, PRX-115 development plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2635894187","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635894187?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:28","pubTimestamp":1778671736,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics highlighted European Commission clearance for an Elfabrio 2 mg/kg every-4-weeks dosing option in stable adult Fabry patients, positioning it as only EU enzyme replacement therapy with a monthly regimen.Chiesi milestone payment tied to dosing update totaled USD 25 million, contributing to USD 33.8 million revenue in Q1 2026.Cash and cash equivalents stood at USD 51.1 million as of March 31, 2026; company reported no debt and no warrants.PRX-115 Phase 2 RELEASE study in uncontrolled gout is enrolling; top-line data targeted for 2H 2027 with dosing arms designed to test every-4-weeks use without methotrexate.Common stock outstanding listed at 80,500,000 shares as of May 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL7HwtR9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635869997","title":"Protalix BioTherapeutics Q1 EPS USD 0.23","url":"https://stock-news.laohu8.com/highlight/detail?id=2635869997","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635869997?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:03","pubTimestamp":1778670192,"startTime":"0","endTime":"0","summary":"May 13 (Reuters) - Protalix BioTherapeutics Q1 operating income USD 21.146 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-MAY-202610:49:42.963 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nRSDmXXwz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635866357","title":"Protalix BioTherapeutics Q1 EPS $0.05 Misses $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635866357","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635866357?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:02","pubTimestamp":1778670148,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is a 200 percent increase over losses of $(0.05) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52517508/protalix-biotherapeutics-q1-eps-0-05-misses-0-06-estimate-sales-33-750m-beat-11-468m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786809","title":"Israel's Protalix Q1 revenue surges on Chiesi milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786809","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786809?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670051,"startTime":"0","endTime":"0","summary":"Israel's Protalix Q1 revenue surges on Chiesi milestoneOverviewIsrael biopharma's Q1 revenue surged yr/yr, driven by $25 mln milestone from ChiesiRevenue from goods sold fell due to timing shift in Pf","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q0GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU0225771236.USD","BK4599","LU0868494617.USD","LU0306806265.USD","LU0321505868.SGD","BK4588","LU1894683348.USD","LU0321505439.SGD","BK4585","BK4568","LU0985481810.HKD","SG9999001176.SGD","LU1066053197.SGD","LU0289739699.SGD","BK4007","IE00BLSP4239.USD","LU1883839398.USD","LU0306807586.USD","IE00B19Z3581.USD","SG9999002224.SGD","SG9999011175.SGD","LU0170899867.USD","IE000M9KFDE8.USD","LU0456855351.SGD","PLX","BK4592","SG9999002232.USD","SG9999003800.SGD","BK4533","LU1057294990.SGD","LU1894683264.USD","BK4581","IE00BLSP4452.SGD","LU0225284248.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","LU0122379950.USD","IE00BBT3K403.USD","BK4534","SG9999013999.USD","IE00B3T34201.USD","LU0058720904.USD","LU0234572021.USD","SG9999001176.USD","BK4550","LU1066051498.USD","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785142","title":"Protalix Q1 FY26 swings to net income of $18.32 million; revenue more than doubled to $33.75 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785142","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785142?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:50","pubTimestamp":1778669442,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics swung to net income of USD 18.32 million, or USD 0.23 per share, from a net loss of USD 3.62 million, or USD  per share.Revenue climbed to USD 33.75 million from USD 10.11 million, driven by USD 26.33 million in license and R&D services revenue that included a USD 25 million milestone from Chiesi tied to European Commission approval of Elfabrio’s 2 mg/kg every-4-weeks dosing.Revenue from selling goods fell to USD 7.42 million from USD 10 million due to a timing shift in Pfizer purchases, partially offset by USD 3.5 million in sales to Chiesi.R&D expenses rose 56% to USD 5.43 million as the Phase 2 RELEASE trial of PRX-115 advanced; cash, cash equivalents, and short-term bank deposits totaled USD 51.1 million at March 31.Full-year 2026 revenue guidance was reaffirmed at USD 78 million-USD 83 million, including the USD 25 million milestone.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL7cQJsp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","SG9999002224.SGD","IE0002270589.USD","IE00BLSP4239.USD","LU0225771236.USD","LU0321505439.SGD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","BK4568","LU0985481810.HKD","LU1057294990.SGD","LU1894683264.USD","IE000M9KFDE8.USD","SGXZ57979304.SGD","SG9999013999.USD","IE00B19Z3581.USD","LU0225284248.USD","LU1023059063.AUD","LU0289739699.SGD","BK4533","BK4599","LU0234572021.USD","BK4588","IE00B3T34201.USD","IE00BBT3K403.USD","LU1066053197.SGD","PLX","LU0306807586.USD","LU0868494617.USD","LU0122379950.USD","SG9999001176.SGD","SG9999011175.SGD","SG9999003800.SGD","LU0058720904.USD","BK4592","LU0170899867.USD","LU0321505868.SGD","LU1066051498.USD","BK4550","LU0306806265.USD","LU1883839398.USD","BK4534","SG9999002232.USD","LU1894683348.USD","SG9999001176.USD","BK4585","BK4007","BK4581","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785985","title":"Press Release: Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785985","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785985?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:50","pubTimestamp":1778669400,"startTime":"0","endTime":"0","summary":"Company to host conference call and webcast today at 8:00 a.m. EDT. -- Elfabrio commercial execution continues following European Commission. approval of the 2 mg/kg every--4--weeks  dosing regimen; $25 million. -- PRX--115 Phase 2 study continues to advance as planned with top--line. -- The Company reaffirms its previously stated 2026 revenue guidance of. -- Cash, cash equivalents, and short--term bank deposits were $51 million as. During the first quarter, the Company continued to execute against its commercial partnerships, advance its clinical and preclinical development programs, and reaffirm its strategic priorities and financial outlook for 2026.-- Protalix and its partner, Chiesi Farmaceutici, continue to support the. -- With the global Fabry market projected to reach approximately $3 bill","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4022","BK4139","PLX","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633824182","title":"Protalix BioTherapeutics updates financial calendar with Q1 results release, conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2633824182","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633824182?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:03","pubTimestamp":1778065431,"startTime":"0","endTime":"0","summary":"Protalix BioTherapeutics to release first-quarter 2026 financial results on May 13, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL3bsvBF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protalix.com","stockEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":0.1055},{"period":"3month","weight":0.3166},{"period":"6month","weight":0},{"period":"1year","weight":0.6375},{"period":"ytd","weight":0.4556}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.736842,"avgChangeRate":0.12158},{"month":2,"riseRate":0.421053,"avgChangeRate":0.054153},{"month":3,"riseRate":0.315789,"avgChangeRate":-0.044755},{"month":4,"riseRate":0.55,"avgChangeRate":0.053145},{"month":5,"riseRate":0.2,"avgChangeRate":-0.049642},{"month":6,"riseRate":0.45,"avgChangeRate":-0.027767},{"month":7,"riseRate":0.4,"avgChangeRate":-0.042671},{"month":8,"riseRate":0.4,"avgChangeRate":-0.007383},{"month":9,"riseRate":0.45,"avgChangeRate":0.049537},{"month":10,"riseRate":0.421053,"avgChangeRate":-0.052252},{"month":11,"riseRate":0.368421,"avgChangeRate":-0.008211},{"month":12,"riseRate":0.421053,"avgChangeRate":-0.008649}],"exchange":"AMEX","name":"Protalix BioTherapeutics","nameEN":"Protalix BioTherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protalix BioTherapeutics(PLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Protalix BioTherapeutics(PLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Protalix BioTherapeutics,PLX,Protalix BioTherapeutics股票,Protalix BioTherapeutics股票老虎,Protalix BioTherapeutics股票老虎国际,Protalix BioTherapeutics行情,Protalix BioTherapeutics股票行情,Protalix BioTherapeutics股价,Protalix BioTherapeutics股市,Protalix BioTherapeutics股票价格,Protalix BioTherapeutics股票交易,Protalix BioTherapeutics股票购买,Protalix BioTherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protalix BioTherapeutics(PLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Protalix BioTherapeutics(PLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction